CN1209163C - 脑膜炎球菌疫苗及其制备方法 - Google Patents
脑膜炎球菌疫苗及其制备方法 Download PDFInfo
- Publication number
- CN1209163C CN1209163C CN 03131108 CN03131108A CN1209163C CN 1209163 C CN1209163 C CN 1209163C CN 03131108 CN03131108 CN 03131108 CN 03131108 A CN03131108 A CN 03131108A CN 1209163 C CN1209163 C CN 1209163C
- Authority
- CN
- China
- Prior art keywords
- group
- meningitis cocci
- group meningitis
- polysaccharide
- membrane protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 229940124731 meningococcal vaccine Drugs 0.000 title abstract 3
- 201000009906 Meningitis Diseases 0.000 claims abstract description 138
- 229960005486 vaccine Drugs 0.000 claims abstract description 100
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 95
- 239000005017 polysaccharide Substances 0.000 claims abstract description 95
- 150000004676 glycans Chemical class 0.000 claims abstract description 94
- 101710116435 Outer membrane protein Proteins 0.000 claims abstract description 72
- 238000010168 coupling process Methods 0.000 claims description 22
- 230000008878 coupling Effects 0.000 claims description 20
- 238000005859 coupling reaction Methods 0.000 claims description 20
- 230000001580 bacterial effect Effects 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 230000003053 immunization Effects 0.000 claims description 14
- 238000004440 column chromatography Methods 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000108 ultra-filtration Methods 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 7
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 239000004411 aluminium Substances 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 235000004252 protein component Nutrition 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 abstract description 3
- 208000013223 septicemia Diseases 0.000 abstract description 3
- 238000011081 inoculation Methods 0.000 description 23
- 238000012360 testing method Methods 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000036039 immunity Effects 0.000 description 13
- 230000005847 immunogenicity Effects 0.000 description 13
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 229940031937 polysaccharide vaccine Drugs 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241000588650 Neisseria meningitidis Species 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 7
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 6
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 238000010241 blood sampling Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 230000006054 immunological memory Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 150000002605 large molecules Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241001478240 Coccus Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940001442 combination vaccine Drugs 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- -1 polysaccharides compound Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- 229910018626 Al(OH) Inorganic materials 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 229960003983 diphtheria toxoid Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000037941 meningococcal disease Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000011046 pyrogen test Methods 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 238000009781 safety test method Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 229940032024 DPT vaccine Drugs 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 125000003651 hexanedioyl group Chemical group C(CCCCC(=O)*)(=O)* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 229940052778 neisseria meningitidis Drugs 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000003257 protein preparation method Methods 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940031351 tetravalent vaccine Drugs 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
接种剂量 | 第一次 IgG GMT | 第二次 IgG GMT | ||
A | C | A | C | |
5μg | 83.47 | 183.90 | 78.95 | 205.30 |
2.5μg | 79.12 | 212.3 | 79.52 | 221.30 |
1.25μg | 43.00 | 73.4 | 56.31 | 94.65 |
0.6125μg | 35.4 | 81.6 | 40.12 | 83.15 |
免疫途径 | 第一次 IgG GMT | 第二次 IgG GMT | ||
A | C | A | C | |
皮下 | 75.69 | 235.1 | 63.20 | 253.43 |
肌肉 | 80.13 | 244.91 | 75.93 | 276.38 |
腹腔 | 82.34 | 213.45 | 64.30 | 231.15 |
免疫针次 | IgG GMT | |
A | C | |
1 | 11.34 | 45.61 |
2 | 83.41 | 251.63 |
3 | 195.43 | 1258.34 |
疫苗批号 | IgG GMT | |
A | C | |
20030101 | 273.56 | 1259.41 |
20030102 | 215.89 | 1315.12 |
20030103 | 258.31 | 1198.35 |
免疫针次 | 采血时间(周) | C群 IgG GMT | A群 IgG GMT | ||
Al(OH)3 | 缓冲生理盐水 | Al(OH)3 | 缓冲生理盐水 | ||
1 | 1 | 4.58 | 18.37 | 6.38 | 25.33 |
2 | 10.39 | 38.05 | 9.12 | 21.51 | |
2 | 1 | 139.80 | 98.12 | 43.10 | 52.35 |
2 | 98.37 | 101.53 | 37.52 | 49.75 | |
3 | 1 | 1350.42 | 637.50 | 225.31 | 183.13 |
2 | 1735.61 | 943.52 | 273.80 | 215.75 |
疫苗批号 | 接种前体重(克) | 观察期接种反应 | 接种后10天体重(克) | 结论 |
20030101 | 348312 | 行动自如,无任何异常情况 | 389375 | 合格 |
20030102 | 323308 | 行动自如,无任何异常情况 | 359350 | 合格 |
20030103 | 329335 | 行动自如,无任何异常情况 | 389383 | 合格 |
疫苗批号 | 接种前体重(克) | 观察期接种反应 | 接种后10天体重(克) | 结论 |
20030101 | 18.319.519.018.619.5 | 行动自如进食正常无异常反应 | 21.323.522.523.124.5 | 合格 |
20030102 | 18.019.319.520.321.0 | 行动自如进食正常无异常反应 | 23.125.024.826.025.9 | 合格 |
20030103 | 20.518.319.019.518.9 | 行动自如进食正常无异常反应 | 24.823.123.024.525.1 | 合格 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03131108 CN1209163C (zh) | 2003-05-12 | 2003-05-12 | 脑膜炎球菌疫苗及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03131108 CN1209163C (zh) | 2003-05-12 | 2003-05-12 | 脑膜炎球菌疫苗及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1457879A CN1457879A (zh) | 2003-11-26 |
CN1209163C true CN1209163C (zh) | 2005-07-06 |
Family
ID=29430558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03131108 Expired - Fee Related CN1209163C (zh) | 2003-05-12 | 2003-05-12 | 脑膜炎球菌疫苗及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1209163C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102633896A (zh) * | 2012-04-23 | 2012-08-15 | 成都欧林生物科技股份有限公司 | Hib多糖纯化工艺 |
CN104829711B (zh) * | 2014-04-08 | 2018-04-03 | 北京天成新脉生物技术有限公司 | 脑膜炎球菌荚膜多糖单克隆抗体及其应用 |
CN104127869B (zh) * | 2014-07-18 | 2015-10-14 | 北京祥瑞生物制品有限公司 | 多价b群脑膜炎球菌蛋白疫苗及其制备方法 |
CN104998255B (zh) * | 2015-06-30 | 2018-08-28 | 北京祥瑞生物制品有限公司 | 新型acyw135群脑膜炎球菌结合疫苗及其制备方法 |
-
2003
- 2003-05-12 CN CN 03131108 patent/CN1209163C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1457879A (zh) | 2003-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1610560A (zh) | 多价脑膜炎球菌多糖-蛋白质缀合疫苗 | |
CN1159064C (zh) | 甲型链球菌多糖免疫原性组合物及方法 | |
CN1163270C (zh) | 修饰的脑膜炎球菌多糖偶联物疫苗 | |
CN103656632B (zh) | 多价肺炎球菌荚膜多糖组合物、其制备方法及应用 | |
CN100462102C (zh) | 脑膜炎球菌多价联合疫苗 | |
WO2016155581A1 (zh) | 一种分离纯化的无细胞百白破-b型流感嗜血杆菌-A群C群脑膜炎球菌联合疫苗及其制备方法 | |
CN1709505A (zh) | 多价细菌荚膜多糖-蛋白质结合物联合疫苗 | |
US10758604B2 (en) | Methods for the prevention of Salmonella infections | |
CN1060408A (zh) | 改进的疫苗组合物 | |
CN101111261A (zh) | 糖偶联物疫苗 | |
CN1404399A (zh) | 调节包括与粘膜体表面接触的疫苗抗原的物质的作用的新的非抗原性粘膜佐剂制剂 | |
US10046042B2 (en) | Meningococcal conjugate vaccine for groups A, C, Y and W135 and a preparation method thereof | |
CN106215183A (zh) | 一种abc群脑膜炎球菌联合疫苗及其制备方法 | |
CN1209163C (zh) | 脑膜炎球菌疫苗及其制备方法 | |
CN1525869A (zh) | 低分子量透明质酸与多肽毒素的免疫原性偶联物 | |
CN1168501C (zh) | 一种多糖-蛋白结合疫苗 | |
CN110917344B (zh) | 一种液体疫苗组合物及其应用 | |
CN1911444A (zh) | 伤寒、副伤寒外膜蛋白疫苗 | |
CN1305527C (zh) | 乙型肝炎治疗疫苗及其制备方法 | |
CN104001166B (zh) | Abc群脑膜炎球菌联合疫苗及其制备方法 | |
CN1314449C (zh) | 乙型脑炎病毒疫苗和脑膜炎球菌结合疫苗组成的联合疫苗 | |
CN1401328A (zh) | 流行性脑脊髓膜炎多糖-蛋白结合疫苗 | |
CN110251667A (zh) | 一种免疫组合制剂及其制备方法和应用 | |
CN106109486A (zh) | 一种组合物及其制备方法与应用 | |
CN113663066B (zh) | 一种肌醇阿拉伯甘露寡糖缀合物及在抗结核疫苗中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ASS | Succession or assignment of patent right |
Owner name: FAN YUZHU Free format text: FORMER OWNER: BEIJING YAOHUA BIOLOGY TECHNOLOGY CO., LTD. Effective date: 20030820 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20030820 Applicant after: Fan Yuzhu Applicant before: Beijing Yaohua Biological Technology Co Ltd |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING XIAN GRUI BIOLOGY PRODUCTS CO., LTD. Free format text: FORMER OWNER: FAN YUZHU Effective date: 20070413 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070413 Address after: Three in 101407 districts in Beijing District of Huairou Yanqi Industrial Development Zone No. 999 Patentee after: Beijing Xiangrui Biological Products Co., Ltd. Address before: 101407 new West Road, Miyun Town, Beijing, Miyun Patentee before: Fan Yuzhu |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 101407 Beijing city Huairou District Yanqi Yanqi Economic Development Zone No. 17 North Street Patentee after: Beijing Xiangrui Biological Products Co., Ltd. Address before: Three in 101407 districts in Beijing District of Huairou Yanqi Industrial Development Zone No. 999 Patentee before: Beijing Xiangrui Biological Products Co., Ltd. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150821 Granted publication date: 20050706 Pledgee: China Development Bank Co Pledgor: Beijing Xiangrui Biological Products Co., Ltd. Registration number: 200501245 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20150821 Registration number: 200501245 Pledgee after: China Development Bank Co Pledgee before: National Development Bank |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Meningococcal vaccine and its preparing method Effective date of registration: 20161115 Granted publication date: 20050706 Pledgee: Shi Jinhong Pledgor: Beijing Xiangrui Biological Products Co., Ltd. Registration number: 2016990000978 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050706 Termination date: 20180512 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220308 Granted publication date: 20050706 Pledgee: Shi Jinhong Pledgor: BEIJING SANROAD BIOLOGICAL PRODUCTS CO.,LTD. Registration number: 2016990000978 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |